Subscribe
shutterstock_1662839302_tada_images
Tada Images / Shutterstock.com
24 March 2022GenericsAlex Baldwin

Novo Nordisk and Sandoz settle Victoza patent suit

Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza (Liraglutide) before the companies were meant to face trial in April.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Novo Nordisk seeks to block Mylan generic
22 August 2019   Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).
Americas
Teva enters settlement with Novo Nordisk to sell Victoza generic
19 March 2019   Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza.
Americas
Novo Nordisk makes $1.1bn bid for biopharma company
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Generics
Novo Nordisk seeks to block Mylan generic
22 August 2019   Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).
Americas
Teva enters settlement with Novo Nordisk to sell Victoza generic
19 March 2019   Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza.
Americas
Novo Nordisk makes $1.1bn bid for biopharma company
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.

More on this story

Generics
Novo Nordisk seeks to block Mylan generic
22 August 2019   Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).
Americas
Teva enters settlement with Novo Nordisk to sell Victoza generic
19 March 2019   Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza.
Americas
Novo Nordisk makes $1.1bn bid for biopharma company
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility